Phase II study of NGR-hTNF, a selective vascular targeting agent (VTA), administered as single agent in patients (pts) with colorectal cancer (CRC) refractory to standard regimens

被引：0
|
作者：
Rimassa, L. [1 ,2 ,3 ,4 ]
Sobrero, A. F. [1 ,2 ,3 ,4 ]
Santoro, A. [1 ,2 ,3 ,4 ]
Andretta, V. [1 ,2 ,3 ,4 ]
Gregorc, V. [1 ,2 ,3 ,4 ]
Sclafani, F. [1 ,2 ,3 ,4 ]
Caprioni, F. [1 ,2 ,3 ,4 ]
Caligaris-Cappio, F. [1 ,2 ,3 ,4 ]
Lambiase, A. [1 ,2 ,3 ,4 ]
Bordignon, C. [1 ,2 ,3 ,4 ]
机构：
[1] Inst Clin Humanitas, Rozzano, Italy
[2] Osped San Martino Genova, Genoa, Italy
[3] Ist Sci San Raffaele, Milan, Italy
[4] MolMed, Milan, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4088
引用
收藏
页数：2
相关论文
共 50 条
  • [1] NGR-hTNF, a vascular targeting agent (VTA), administered as single agent in patients (pts) with colorectal cancer (CRC) failing standard regimens: a phase II study
    Rimassa, L.
    Santoro, A.
    Sobrero, A. F.
    Sclafani, F.
    Gregorc, V.
    Andretta, V.
    Tronconi, M. C.
    Cappio, F. Caligaris
    Lambiase, A.
    Bordignon, C.
    EJC SUPPLEMENTS, 2009, 7 (02): : 340 - 340
  • [2] A phase II study of NGR-hTNF, a novel vascular targeting agent (VTA), administered as single agent at low dose in patients (pts) with colorectal cancer (CRC) refractory to standard regimens
    Santoro, A.
    Andretta, V.
    Gregorc, V.
    Rimassa, L.
    Bennicelli, E.
    Sclafani, F.
    Caprioni, F.
    Caligaris-Cappio, F.
    Lambiase, A.
    Bordignon, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [3] PHASE II STUDY OF NGR-HTNF, A NOVEL VASCULAR TARGETING AGENT (VTA), ADMINISTERED AS SINGLE AGENT AT LOW DOSE IN PATIENTS (PTS) WITH COLORECTAL CANCER (CRC) REFRACTORY TO STANDARD REGIMENS
    Rimassa, L.
    Sobrero, A.
    Santoro, A.
    Andretta, V.
    Gregorc, V.
    Sclafani, F.
    Caprioni, F.
    Caligaris-Cappio, F.
    Lambiase, A.
    Bordignon, C.
    ANNALS OF ONCOLOGY, 2008, 19 : 136 - 136
  • [4] Phase II study of two doses of NGR-hTNF, a vascular targeting agent (VTA), combined with capecitabine/oxaliplatin (XELOX) in colorectal cancer (CRC) patients failing standard regimens
    Sobrero, A. F.
    Pessino, A.
    Andretta, V.
    Bennicelli, E.
    Fornarini, G.
    Caprioni, F.
    Comandini, D.
    Orsino, L.
    Lambiase, A.
    Bordignon, C.
    EJC SUPPLEMENTS, 2009, 7 (02): : 341 - 341
  • [5] Phase I study of NGR-hTNF, a vascular targeting agent (VTA), in combination withcisplatin in refractory patients (pts) with solid tumours
    Citterio, G.
    De Braud, F. G.
    Gregorc, V.
    De Pas, T. M.
    Noberasco, C.
    Boselli, S.
    Giovannini, M.
    Cappio, F. Caligaris
    Lambiase, A.
    Bordignon, C.
    EJC SUPPLEMENTS, 2009, 7 (02): : 129 - 129
  • [6] A phase II study of NGR-hTNF, a novel vascular targeting agent (VTA), administered as single agent at low dose in pretreated patients (pts) with advanced hepatocellular carcinoma (HCC)
    Citterio, G.
    Santoro, A.
    Scalamogna, R.
    Pressiani, T.
    Gregorc, V.
    Rossoni, G.
    Donadoni, G.
    Caligaris-Cappio, F.
    Lambiase, A.
    Bordignon, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [7] Phase II study of NGR-hTNF, a selective vascular targeting agent, in patients with metastatic colorectal cancer after failure of standard therapy
    Santoro, Armando
    Rimassa, Lorenza
    Sobrero, Alberto F.
    Citterio, Giovanni
    Sclafani, Francesco
    Carnaghi, Carlo
    Pessino, Anna
    Caprioni, Francesco
    Andretta, Valeria
    Tronconi, Maria Chiara
    Finocchiaro, Giovanna
    Rossoni, Gloria
    Zanoni, Angela
    Miggiano, Chiara
    Rizzardi, Gian-Paolo
    Traversari, Catia
    Caligaris-Cappio, Federico
    Lambiase, Antonio
    Bordignon, Claudio
    EUROPEAN JOURNAL OF CANCER, 2010, 46 (15) : 2746 - 2752
  • [8] Phase II study of NGR-hTNF, a selective vascular targeting agent (VTA), in previously treated patients (pts) with advanced hepatocellular carcinoma (HCC)
    Santoro, A.
    Citterio, G.
    Pressiani, T.
    Gregorc, V.
    Rimassa, L.
    De Braud, F. G.
    Rossoni, G.
    Cappio, F. Caligaris
    Lambiase, A.
    Bordignon, C.
    EJC SUPPLEMENTS, 2009, 7 (02): : 395 - 395
  • [9] Phase Ib study of NGR-hTNF, a selective vascular targeting agent (VTA), in combination with cisplatin in patients with refractory solid tumors
    Citterio, G.
    De Braud, F. G.
    Gregorc, V.
    De Pas, T. M.
    Scalamogna, R.
    Boselli, S.
    Giovannini, M.
    Caligaris-Cappio, F.
    Lambiase, A.
    Bordignon, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [10] Phase II study of NGR-hTNF, a selective vascular targeting agent (VTA), in previously treated patients with hepatocellular carcinoma (HCC)
    Santoro, A.
    Citterio, G.
    Pressiani, T.
    De Braud, F. G.
    Gregorc, V.
    Rossoni, G.
    Donadoni, G.
    Caligaris-Cappio, F.
    Lambiase, A.
    Bordignon, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
12345